Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

被引：0
作者：
Teddy Kosoglou
Walter K. Kraft
Bharath Kumar
Paul Statkevich
Fengjuan Xuan
Lei Ma
Lisa K. Jennings
James E. Schiller
Ronald B. Langdon
David L. Cutler
机构：
[1] Merck Sharp & Dohme Corp.,Department of Pharmacology and Experimental Therapeutics
[2] Thomas Jefferson University,Clinical Pharmacology, Merck Research Laboratories
[3] University of Tennessee Health Science Center,undefined
[4] Merck Sharp & Dohme Corp.,undefined
来源：
European Journal of Clinical Pharmacology | 2012年 / 68卷
关键词：
Vorapaxar; SCH 530348; PAR-1; Renal disease; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1049 / 1056
页数：7
相关论文
共 50 条
  • [21] PHARMACOKINETICS AND PHARMACODYNAMICS OF THE 3 ISOMERS OF MIVACURIUM IN HEALTH, IN END-STAGE RENAL-FAILURE AND IN PATIENTS WITH IMPAIRED RENAL-FUNCTION
    HEADRAPSON, AG
    DEVLIN, JC
    PARKER, CJR
    HUNTER, JM
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1995, 75 (01) : 31 - 36
  • [22] Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
    Pastores, Gregory M.
    Boyd, Ellen
    Crandall, Kerry
    Whelan, Alison
    Piersall, Linda
    Barnett, Natalie
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) : 1920 - 1925
  • [23] THE EFFECT OF HEMODIALYSIS ON THE PHARMACOKINETICS OF TENOXICAM IN PATIENTS WITH END-STAGE RENAL-DISEASE
    ALGHAMDI, MS
    ALMOHANNA, FA
    ALMUSTAFA, ZH
    ALSAEED, IS
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (02) : 197 - 199
  • [24] Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD)
    Frank, T
    Bitsch, R
    Maiwald, J
    Stein, G
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (09) : 449 - 455
  • [25] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
    Thariat, Juliette
    Etienne-Grimaldi, Marie-Christine
    Launay-Vacher, Vincent
    Soto-Matos, Arturo
    Fernandez-Teruel, Carlos
    Ghafari, Thomas
    Marcy, Pierre-Yves
    Milano, Gerard
    Renee, Nicole
    Gastaud, Lauris
    Thyss, Antoine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1363 - 1367
  • [26] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
    Juliette Thariat
    Marie-Christine Etienne-Grimaldi
    Vincent Launay-Vacher
    Arturo Soto-Matos
    Carlos Fernandez-Teruel
    Thomas Ghafari
    Pierre-Yves Marcy
    Gérard Milano
    Nicole Renée
    Lauris Gastaud
    Antoine Thyss
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 68 : 1363 - 1367
  • [27] BIOAVAILABILITY OF LABETALOL IN PATIENTS WITH END-STAGE RENAL-DISEASE
    LUKE, DR
    AWNI, WM
    HALSTENSON, CE
    OPSAHL, JA
    MATZKE, GR
    [J]. THERAPEUTIC DRUG MONITORING, 1992, 14 (03) : 203 - 208
  • [28] Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment
    Manitpisitkul, Prasarn
    Curtin, Christopher R.
    Shalayda, Kevin
    Wang, Shean-Sheng
    Ford, Lisa
    Heald, Donald L.
    [J]. EPILEPSY RESEARCH, 2014, 108 (05) : 891 - 901
  • [29] Pharmacokinetics of Tofacitinib, a Janus Kinase Inhibitor, in Patients With Impaired Renal Function and End-Stage Renal Disease
    Krishnaswami, Sriram
    Chow, Vincent
    Boy, Mary
    Wang, Cunshan
    Chan, Gary
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (01): : 46 - 52
  • [30] Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics
    Peyro-Saint-Paul, Laure
    Bechade, Clemence
    Cesbron, Alexandre
    Debruyne, Daniele
    Brionne, Marie
    Brucato, Sylvie
    Hanoy, Melanie
    Dumont, Audrey
    Briant, Anais R.
    Parienti, Jean-Jacques
    Lobbedez, Thierry
    Ficheux, Maxence
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (08) : 1918 - 1920
12345